We’ve had a busy few months here at Immunitrack and are delighted to announce several new funding and collaboration updates.
PrDx – artificial intelligence epitope-prediction platform
In November, we secured a second-round investment of 6 million DKK from Tingle Creek, a British-based business angel. Alongside an investor loan of 2 million DKK from Danish state investment fund ‘Vækstfonden’. This investment will further strengthen ongoing commercial activities and allow further development of our artificial intelligence (AI) epitope-prediction platform PrDx, which has already shown superior performance on certain parameters when compared to other existing solutions. We expect to release the first version in the beginning of 2022.
PrDx in combination with our high-throughput in vitro NeoScreen® platform for T cell epitope immunogenicity prediction is anticipated to improve vaccine potency and safety as well as speed up the development of personalised cancer vaccines by accurately predicting the epitopes most likely to provoke the desired immunological response.
National Center for Cancer Immune Therapy
In addition, we have also strengthened our collaboration with the National Center for Cancer Immune Therapy (CCIT-DK), at Herlev Hospital in Denmark, a leading Danish center for research and clinical implementation of novel immunotherapy. This includes appointment of a postdoctoral researcher for a 3-year period in collaboration with the research group of professor Mads Hald Andersen at CCIT-DK. This post doc stipendium was awarded by the Danish Innovation Foundation (Innovationsfonden).
The unique combination of Immunitrack’s epitope prediction platform and the collaboration with CCIT-DK presents a complete unmatched R&D solution for cancer patient tumour sequencing and bioinformatics analysis, high-throughput peptide synthesis, T cell epitope prediction and assessment, as well as immune monitoring of patients in the clinic.
High throughput screening of T cell epitopes
In recent years, Immunitrack has invested heavily in developing a semi-automated platform for high throughput screening of T cell epitopes from several viruses including SARS-CoV-2 as well as certain cancers. The T cell response depends on human leukocyte compositions (HLA), which are polymorphic receptors that are present in varying abundances across the 4 major ethnic groups (Hispanic, African, Asian and Caucasian). The uniqueness of this platform is its capacity to generate data across a large number of HLA receptors (covering all ethnic groups) that has a strong correlation with patient specific T-cell response.
For further information, please contact:
Stephan Thorgrimsen, CEO